Furthermore, combination therapies involving PD-1/PD-L1 inhibitors and other immune checkpoint modulators, such as LAG-3 inhibitors, have led to an even higher incidence of myocarditis, with up to 1.7% of patients experiencing this adverse event, compared to 0.6% with single-agent PD-1/PD-L1 therapy (179). The gene discussed is LAG3; the disease is myocarditis.